WLWenjie Liu

Wenjie Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wenjie Liu has a total of 67 co-authors. Here are the top co-authors by number of shared publications:

  • Chengxi Liu

    Department of Anesthesiology, Hengyang Medical School, The Second Affiliated Hospital, University of South China, China

    2 shared publications
  • Deming Wang

    Department of Anesthesiology, the Second Affiliated Hospital, University of South China, Hengyang, China

    2 shared publications
  • Leiyu Xie

    Department of Critical Care Medicine, The Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, China

    2 shared publications
  • Liang Zeng

    Department of Emergency, The Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan province, China

    2 shared publications
  • Lili He

    Department of Anesthesiology, the Second Affiliated Hospital, University of South China, Hengyang, China

    2 shared publications
  • Lin Ling

    The Second Affiliated Hospital, National Regional Key Cities and Sub-central Cities in Hunan Province Hengyang Academician and Expert International Academic Exchange High Tech University, Building A First-class Discipline for Trauma and Critical Care, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan province, China

    2 shared publications

Latest Publications

  • Open Access

    Ketogenic diet mitigates sepsis-related acquired weakness in conjunction with SIRT3 upregulation and macrophage M2 polarization

    by Yanmei Miao, Yuhao Peng, Yushen Yang, Shaolin Chen, Jiamei Song, Leiyu Xie, Zhijia Huang, Xinglong Ma, Wenjie Liu, Peng Xie

  • Open Access

    The TLR9-CXCL2 complex orchestrates mitochondrial DNA-driven regulatory B cell dysfunction in acute lung injury

    by Ren Jing, Yiming Fu, Yaoli Hou, Sheng He, Nan Wu, Lili He, Zhiying Zeng, Song Liu, Qian Zhang, Deming Wang, et al.

  • Open Access

    Early ICU glycemic trajectory phenotypes predict short- and long-term mortality in critically ill patients: a dual-database cohort study

    by Deyu Kong, Yang Long, Tingting Huang, Yonghu Zhang, Wen-Jie Liu, Cheng-Xi Liu, Shan Liu


  • Open Access

    Acute Lung Injury: From Molecular Circuits to System‐Level Therapeutics

    by Yaoli Hou, Sheng He, Lili He, Kun Liu, Wen Tang, Deming Wang, Jing Gui, Zhiying Zeng, Yan Wang, Wenjie Liu, et al.

    Acute lung injury (ALI) and its severe manifestation, acute respiratory distress syndrome (ARDS), remain critical conditions with persistently high mortality. The failure to develop effective pharmacotherapies stems largely from reductionist approaches focused on isolated linear pathways. This review synthesizes recent breakthroughs redefining ALI as dysregulation of integrated pathological networks spanning immunity, metabolism, and cell death. We systematically analyze three interconnected core circuits: cGAS–STING as a central danger signal integrator, immunometabolic reprogramming as fuel for sustained inflammation, and the programmed cell death network—particularly PANoptosis—as executor of tissue damage. We further elucidate how ALI manifests as a multiorgan communication disorder, with the brain and gut actively shaping pulmonary inflammation. The convergence of single‐cell technologies, multiomics profiling, and computational modeling has deconstructed ARDS heterogeneity into clinically actionable endotypes (hyperinflammatory C1, hypoinflammatory C2) with differential treatment responses. This network‐based understanding is catalyzing a therapeutic shift toward rationally designed poly‐pharmacology, precision immunotherapies, and advanced platforms integrating smart nanomaterials with endogenous systems. By embracing this holistic perspective, we chart a course toward mechanism‐based, personalized interventions that move beyond supportive care to genuine disease modification.


  • Open Access

    Effect of ciprofol with etomidate on the occurrence of hypotension in elderly patients undergoing upper gastrointestinal endoscopy: a prospective randomized controlled study

    by Zeyu Guo, Yuan Xiao, Xinru Li, You Wang, Yi Yang, Chengxi Liu, Wenjie Liu

    Ciprofol is increasingly used for endoscopic sedation due to its reduced injection pain, but evidence regarding its safety when combined with etomidate in elderly patients remains limited. This study evaluated the efficacy and safety of ciprofol–etomidate compared with ciprofol alone and propofol–etomidate in elderly patients undergoing upper gastrointestinal endoscopy. In this randomized controlled trial, 402 patients aged ≥ 60 years scheduled for upper gastrointestinal endoscopy were assigned to one of three groups: ciprofol–etomidate (EC: 0.3 mg/kg ciprofol + 0.12 mg/kg etomidate), ciprofol (C: 0.4 mg/kg) alone, or propofol–etomidate (EP: 1.2 mg/kg propofol + 0.12 mg/kg etomidate). All patients received remifentanil 0.3 µg/kg before sedation. The primary outcome was hypotension incidence. Secondary outcomes included sedation success, vital signs, and other adverse events. Hypotension incidence differed significantly among groups (EC: 64.5%, C: 80.9%, EP: 75.2%; p = 0.008), with a lower rate in the EC group versus the C group (p = 0.003). Injection pain was rare in both EC (0.7%) and C (1.5%) groups compared with EP (9.0%; p < 0.001). Induction time was longer in EC and C groups than in EP. Recovery and discharge times were prolonged in the C group compared with EP. Other adverse events, including bradycardia, hypoxemia, nausea, vomiting, dizziness, and tremors, did not differ significantly among groups. The combination of ciprofol and etomidate offers effective sedation, reducing hypotension compared with ciprofol alone and injection pain compared with propofol–etomidate, and may therefore represent a safer alternative for elderly patients undergoing upper gastrointestinal endoscopy. Chinese Clinical Trial Registry, ChiCTR2300077770 (date: 20/11/2023). The online version contains supplementary material available at 10.1186/s12871-026-03767-2.

  • Open Access

    Impact of early dexmedetomidine administration on short‐ and long‐term outcomes in critically traumatic brain injury patients: A retrospective study using the MIMIC‐IV database

    by Yang Long, Long‐Zhen Liu, Xiao‐Xue Tan, Yong‐Hu Zhang, Cheng‐Xi Liu, Shan Liu, Wen‐Jie Liu

    Traumatic brain injury (TBI) causes significant mortality. Dexmedetomidine (DEX) shows neuroprotective potential in animals, but clinical evidence remains inconsistent. We evaluated the impact of early DEX, initiated within 48 h of admission with a treatment duration of at least 4 h, on survival in intensive care unit (ICU) patients with TBI using the Medical Information Mart for Intensive Care‐IV (MIMIC‐IV) database. Outcomes included 28‐day, hospital, and 1‐year mortality, analyzed via propensity score matching (PSM), multivariable Cox models, and subgroup analyses. Of 2378 patients, 241 received DEX. After PSM (235 pairs), early DEX use significantly reduced 28‐day (HR 0.45, 95% CI 0.30–0.69, p < 0.001) and hospital mortality (HR 0.25, 95% CI 0.15–0.42, p < 0.001). These results remained robust across sensitivity analyses. Similarly, 1‐year mortality decreased (HR 0.64, 95% CI 0.47–0.87, p < 0.01) and further supported by the Boruta algorithm, although inverse probability of treatment weighting analysis showed only a non‐significant trend ( p = 0.08). Survival benefits were more pronounced in patients aged <65 and those requiring mechanical ventilation. In conclusion, early DEX use is associated with improved short‐ and long‐term survival in ICU patients with TBI, particularly in younger individuals and those requiring mechanical ventilation. Randomized controlled trials are warranted to establish causality.

  • Top Cited Papers
    Open Access

    Mast cell–expressed Mrgprb2/MRGPRX2 mediates gout pain and inflammation via a neuroimmune axis

    by Lin Yang, Chengxi Liu, Jin Xiao, Yu Song, Huan Chen, Dan Li, Cong Zou, Tao Hong, Yinglan Liu, Dake Qi, et al.

    Acute severe joint pain is a major symptom in gouty arthritis (GA), and its adequate treatment represents an unmet medical need. Mrgprb2, a specific mast cell receptor, has been implicated in the generation of chronic pain by mobilizing mast cell degranulation, yet its significance in GA pain and joint inflammation is still not well defined. Here, we found that Mrgprb2 was expressed in mouse synovial mast cells. In a murine model of GA, acute blockade or genetic deletion of Mrgprb2 significantly attenuated arthritis pain and hyperexcitability of joint nociceptors with significant reductions in innate immune cell recruitment in the synovium. Under naive conditions, activation of synovial Mrgprb2 was sufficient to excite peripheral terminals of joint nociceptors to induce acute joint hypernociception via the mobilization of mast cell degranulation. Additionally, the level of the neuropeptide substance P (SP) was elevated in the synovium of GA model mice. Using humanized MRGPRX2-knockin mice, we revealed that SP contributed to joint pain and inflammation by activating mast cells through Mrgprb2/MRGPRX2. These findings suggest that synovial mast cell–expressed Mrgprb2/MRGPRX2 merits consideration as a key neuroimmune player and a potential therapeutic target for treating GA pain and joint inflammation.


  • Open Access

    Ketogenic diet in treating sepsis-related acquired weakness: is it friend or foe?

    by Yanmei Miao, Leiyu Xie, Shaolin Chen, Xiaoming Zhang, Wenjie Liu, Peng Xie

    Background: Sepsis is the body’s extreme response to an infection leading to organ dysfunction. Sepsis-related acquired weakness (SAW), a critical illness closely related to metabolic disorders, is characterized by generalized sepsis-induced skeletal muscle weakness, mainly manifesting as symmetrical atrophy of respiratory and limb muscles. Muscle accounts for 40% of the body’s total mass and is one of the major sites of glucose and energy absorption. Diet affects skeletal muscle metabolism, which further impacts physiology and signaling pathways. The ketogenic diet (KD) is a high-fat, low-carbohydrate diet that has shown benefits in patients with a variety of neuromuscular disorders. Patients with SAW are in a hypermetabolic state and can consume approximately 1% of total body muscle mass in a day. Due to the decreased total body energy expenditure secondary to starvation, skeletal muscles enter a low metabolic state, with reduced gluconeogenesis and protein consumption and elevated levels of ketone bodies. The latest research suggests that KD may be a new strategy for SAW prevention and treatment, but its mechanism is still unclear.Objective: Our article aims to explore the effect and mechanism of KD on SAW. And we hope that our review will inspire further research on the KD and foster the exploration of novel strategies for combating SAW.Methods: Search medical databases and related academic websites, using keywords such as “Sepsis-related acquired weakness,” “ketogenic diet,” and “skeletal muscle,” and select representative literature. Using the method of induction and summary, analyze the effect and mechanism of KD on SAW.Results: Compared with early nutrition, KD has a more protective effect on SAW, but its mechanism is complex. Firstly, KD can alter energy metabolism substrates to affect SAW’s energy metabolism; Secondly, KD can directly act as a signaling molecule to improve mitochondrial function in skeletal muscle and stimulate skeletal muscle regeneration signaling molecules; Thirdly, KD can affect the gut microbiota to exert anti-inflammatory effects, enhance immunity, and thus protect SAW.Conclusion: KD has a protective effect on SAW, which includes improving energy metabolism, stimulating muscle regeneration signals, optimizing gut microbiota composition, and reducing inflammation and oxidative stress.


  • Open Access

    Survival predictor in emergency resuscitative thoracotomy for blunt trauma patients: Insights from a Chinese trauma center

    by Shan Liu, Lin Ling, Yong Fu, Wen-Chao Zhang, Yong-Hu Zhang, Qing Li, Liang Zeng, Jun Hu, Yong Luo, Wen-Jie Liu


  • Open Access

    The gut microbiota and post-traumatic major depression disorder: insights from bidirectional two-sample Mendelian randomization

    by Shan Liu, Yu Wang, Yonghu Zhang, Liang Zeng, Lin Ling, Yong Luo, Wenjie Liu

    Background: Exposure to trauma is often associated with an increased incidence of Major Depressive Disorder (MDD), yet the mechanisms underlying MDD development post-trauma remain elusive. The microbiota-gut-brain axis has been implicated in neuropsychiatric disorders, suggesting its potential role in post-traumatic MDD (PTMDD) development. Our study aimed to assess the significance of the gut microbiome-brain interaction in PTMDD.Methods: We conducted a bidirectional two-sample Mendelian Randomization (MR) analysis to investigate the causal relationship between the gut microbiota and both PTMDD and trauma exposure in MDD. Genome-wide association study (GWAS) summary datasets for PTMDD and trauma exposure in MDD, both derived from the UK Biobank. The PTMDD dataset included 24,090 individuals (13,393 cases and 10,701 controls), while the dataset for trauma exposure in MDD comprised 22,880 participants (13,393 cases and 9,487 controls). Additionally, gut microbiota data from the MiBioGen consortium included 14,306 European individuals across 18 diverse cohorts.Results: Our research identified a significant negative association between the phylum Verrucomicrobia (odds ratio (OR) [95% confidence interval (CI)] =0.799 [0.684–0.933], P=0.005) and the risk of developing PTMDD, suggesting a protective role for Verrucomicrobia against PTMDD. Conversely, our findings indicate no causal effects of the gut microbiota on trauma exposure in MDD. However, reverse analysis revealed that both PTMDD and MDD influence certain bacterial traits, affecting 5 and 9 bacterial traits, respectively. Moreover, Verrucomicrobia (OR [95% CI] = 1.166 [1.051 - 1.294], P=0.004) was found to be positively impacted by trauma exposure in MDD.Conclusion: Our findings provide a cause-and-effect relationship between the gut microbiota and PTMDD, contributing to our understanding of the microbiota-gut-brain axis and its role in neuropsychiatric disorder development after trauma. This information provides an opportunity for new treatment and prevention methods which are aimed at the gut-brain interaction.